Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
T14 TJ DaRenTang USD
1.1900.0000.00%
10 Minutes Delay
Market Close
02/07 17:06 CCT
High
1.220
Open
1.210
Turnover
417.80K
Low
1.190
Pre Close
1.190
Volume
347.00K
Price Forecast
News
Comment
Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Jumps 8.3% This Week, Though Earnings Growth Is Still Tracking Behind Three-year Shareholder Returns
By buying an index fund, you can roughly match the market return with ease. But if you choose individual stocks with prowess, you can make superior returns. For example, Tianjin Pharmaceutical Da Re
Those Who Invested in Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Three Years Ago Are up 67%
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SGX:T14) Largest Shareholders Are Individual Investors With 49% Ownership, Private Companies Own 43%
Tianjin Pharmaceutical Profit Jumps 31% in Q3 on Higher Revenue
02:36 AM EDT, 10/31/2022 (MT Newswires) -- Tianjin Pharmaceutical Da Ren Tang Group's (SGX:T14) profit attributable to owners of the parent rose 31% to 260.2 million yuan ($35.7 million) in the third
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SGX:T14) Biggest Owners Are Individual Investors Who Got Richer After Stock Soared 7.6% Last Week
Every investor in Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie
Tianjin Pharmaceutical to Buy Controlling Stake in NewScen Coast Bio for $6 Million
07:36 AM EDT, 09/09/2022 (MT Newswires) -- Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) agreed to subscribe to up to 5.4 million shares in NewScen Coast Bio-Pharmaceutical at 8 yuan apiece for a
Tianjin Zhongxin Board OKs Use of $52 Million Placement Proceeds
08:07 AM EDT, 08/09/2022 (MT Newswires) -- The board of Tianjin Zhongxin Pharmaceutical Group (SGX:T14) approved the temporary use of 350 million yuan ($51.8 million) from the proceeds of a share plac
Tianjin Zhongxin Pharmaceutical Posts Lower Profit in January-March
03:51 AM EDT, 05/02/2022 (MT Newswires) -- Tianjin Zhongxin Pharmaceutical Group (SGX:T14) posted a lower net profit attributable to owners of the parent of 199.6 million yuan ($30.2 million) in the t
Tianjin Zhongxin Pharmaceutical Elects New Chairman; Shares Slip 3%
01:46 AM EST, 12/29/2021 (MT Newswires) -- The board of Tianjin Zhongxin Pharmaceutical Group (SGX:T14) has approved the appointment of Zhang Mingrui as its new chairman. Mingrui will remain chairman
The latest announcement of Lisheng Pharmaceutical: subsidiary cefdinir dispersible tablets pass consistency evaluation
According to Lisheng Pharmaceutical announcement, Tianjin Central Pharmaceutical Co., Ltd., a subsidiary of the company, received a "Drug Supplementary Application approval" (batch number: 2021B03871) and a "Drug Supplementary Application approval" (batch number: 2021B03872) of 0.1g cefdinir dispersible tablets (hereinafter referred to as "the drug") issued by the State Drug Administration. The two specifications of the drug (0.1g X 50mg) passed the generic drug quality and efficacy consistency evaluation. The third quarterly report of 2021 of Lisheng Pharmaceutical shows that the company's main revenue is 836 million yuan, down 8.71% from the same period last year, and the net profit of its mother is 9771.
Company Overview
More
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.
CEO： --
Market： --
Paper Trade
More
Watchlist
No Stock Yet